Portman Square Capital’s Biogen BIIB Stock Holding History

Portman Square Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,361	Closed	-$656K	–	386
2023 Q1	$656K	Buy	+2,361	New	+$653K	0.03%	237

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Portman Square Capital's BIIB Position: Q2 2023 in Review

Portman Square Capital sold out of Biogen (BIIB) in Q2 2023, closing a stake of 2,361 shares — an estimated $656K sold.

Portman Square Capital first reported a position in BIIB in Q1 2023 and held it in 1 quarter. The position peaked at $656K in Q1 2023. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

Portman Square Capital reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
Portman Square Capital sold 2,361 Biogen shares in Q2 2023, an estimated $656K.
Portman Square Capital first reported a position in Biogen in Q1 2023 and held it in 1 quarter.
Portman Square Capital's Biogen position peaked at $656K in Q1 2023.
1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Portman Square Capital's 13F filing for Q2 2023, filed 26 Jul 2023.